IRLAB Therapeutics (OMX: IRLAB-A)

Last close As at 22/02/2025

SEK14.40

0.30 (2.13%)

Market capitalisation

SEK731m

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

Latest Insights

View More
IRLAB Therapeutics_resized

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Kristina Torfgård

    CEO

  • Kristina Torfgård

    CEO

  • Viktor Siewertz

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free